Fibrosis Frontiers: From Basic Mechanisms to Precision Therapies (S6)
January 1-4, 2027
| Location to be Determined
Rafael Kramann, Rebekka Schneider-Kramann and Neil C. Henderson
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
Saturday, January 2, 2027
| 8:00–9:00 AM |
Welcome and Keynote Address |
|
| |
Carine Boustany †, Boehringer Ingelheim
Drug Discovery in Fibrosis |
|
| 9:00–11:15 AM |
Developing Novel Therapeutics in Fibrotic Disease |
|
| |
Thomas A Wynn †, Pfizer
Anti-Inflammatory Therapeutics in Organ Fibrosis |
|
| |
Paul J. Yaworsky †, Mediar Therapeutics
Targeting EphrinB2 and WISP1 in Liver and Pulmonary Fibrosis |
|
| |
Catherine Hines †, GlaxoSmithKline
Biomarkers and Imaging as Readouts in Clinical Testing |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 11:15–12:15 PM |
Meet the Editors |
|
| 12:15–1:00 PM |
Poster Setup |
|
| 12:15–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
From Identification of Novel Therapies to Early Clinical Testing in Fibrosis |
|
| |
Lisa Lancaster †, Vanderbilt University Medical Center
Endpoints in Clinical Trials in Fibrosis |
|
| |
Rebekka Schneider †, Erasmus MC
From Single Cell Genomics to Novel Targets in Fibrotic Disease and Clinical Testing |
|
| |
Frank A. Anania †, US Food and Drug Administration
Regulatory Steps Towards Approval of Novel Antifibrotic Therapies |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Mapping Fibrotic Disease using Single Cell and Spatial Genomics |
|
| |
Rafael Kramann, RWTH Aachen University
Mapping Kidney and Cardiac Fibrosis to Identify Novel Therapeutic Targets |
|
| |
Neil C. Henderson, Institute of Regeneration and Repair, University of Edinburgh
Spatial Mapping of Human Liver Fibrosis |
|
| |
Bethan Psaila †, University of Oxford
Single Cell Mapping of Myelofibrosis |
|
| |
Benjamin D. Humphreys †, Washington University
Single Cell and Spatial Genomics to Map Kidney Fibrosis |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–12:00 PM |
Panel Discussion 1: How to Launch a Startup |
|
| 12:00–1:00 PM |
Poster Setup |
|
| 12:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Fibrosis in Cancer and Aging |
|
| |
Natalie J. Torok †, Stanford University
The Role of Matrix in Liver Cancer Progression and Aging |
|
| |
Simon Mendez-Ferrer †, University of Cambridge
Mechanisms of Fibrosis Hematopoietic Malignancies |
|
| |
Melanie Koenigshoff †, University of Pittsburgh
Role of Senescence and Aging in Pulmonary Fibrosis |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Organ Specific and Conserved Mechanisms of Organ Fibrosis |
|
| |
Jörg H.W. Distler †, University Hospital Düsseldorf
Mechanisms of Pulmonary and Skin Fibrosis |
|
| |
Vincent F Fiore †, Boehringer Ingelheim
Mechanisms of Fibrosis in IBD, Boehringer Ingelheim |
|
| |
Katalin Susztak †, University of Pennsylvania
Mechanisms of Kidney Fibrosis |
|
| |
Kory J. Lavine †, Washington University School of Medicine
Mechanisms of Cardiac Fibrosis |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–12:00 PM |
Panel Discussion 2: Why Are We not Seeing Progress / Therapeutic Success in Some Areas? What Are We Missing and How can We Address these Challenges/ Lessons from Clinical Trials? |
|
| 12:00–5:00 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: AI & Big Data in Drug Development |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:45 PM |
Need for Multimodal Therapies, New Modalities and Lessons Learned from Clinical Trials |
|
| |
Grant Budas †, Gilead
Multimodal Therapies for Fibrotic Disease |
|
| |
Shelia M. Violette †, Q32 Bio
Immunotherapies and New Modalities for Fibrotic Disease |
|
| |
Scott L Friedman †, Icahn School of Medicine at Mount Sinai
Lessons Learned from Clinical Trials and Regulatory Aspects in Fibrotic Disease |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
